Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron’s Strategic R&D and Financial Health Underpin Buy Rating TipRanks Sep. 24, 2024, 04:48 AM ...

Regeneron’s pipeline is a key differentiator, particularly in oncology, with significant progress in submissions for linvoseltamab and odronextamab, and positive data for Libtayo in adjuvant CSCC.